Application of lipid-based formulations in drug discovery

Journal of Medicinal Chemistry

Volumn 55, Issue 18, 2012, Pages 7945-7956

  Chen, Xue Qing ^a   Gudmundsson, Olafur S ^a   Hageman, Michael J ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPRYOL 90; CAPTEX 300; CAPTEX 355; CAPTEX 500; CREMOPHOR; GELUCIRE; IMWITOR 491; LABRAFAC; LABRASOL; LAUROGLYCOL 90; LIPID; MAISINE; OCTANOIN; PECEOL; PEGLICOL 5 OLEATE; PLURO OLEIQUE CC497; POLYSORBATE 20; POLYSORBATE 80; SOLUTOL HS 15; TRIACETIN; UNCLASSIFIED DRUG;

DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG FORMULATION; DRUG SOLUBILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPID SOLUBILITY; LIPOPHILICITY; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG DISCOVERY; FEASIBILITY STUDIES; HUMANS; LIPIDS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84866869526     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3006433     Document Type: Review

References (83)

1. Strickley, R. G. Currently Marketed Oral Lipid-Based Dosage Forms: Drug Products and Excipients. In Oral Lipid-Based Formulations: Enhancing the Bioavailability of Poorly Water-Soluble Drugs; Hauss, D. J., Ed.; Informa Healthcare: New York, London, 2007; pp 1-31.
2. Fatouros, D. G.; Karpf, D. M.; Nielsen, F. S.; Mullertz, A. Clinical studies with oral lipid based formulations of poorly soluble compounds Ther. Clin. Risk Manage. 2007, 3, 591-604
3. Humberstone, A. J.; Charman, W. N. Lipid-based vehicles for the oral delivery of poorly water soluble drugs Adv. Drug Delivery Rev. 1997, 25, 103-128
4. Charman, W. N. Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts J. Pharm. Sci. 2000, 89, 967-978
5. Porter, C. J. H.; Trevaskis, N. L.; Charman, W. N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs Nat. Rev. Drug Discovery 2007, 6, 231-248
6. Yang, S.; Gursoy, R. N.; Lambert, G.; Benita, S. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors Pharm. Res. 2004, 21, 261-270
7. Porter, C. J. H.; Kaukonen, A. M.; Taillardat-Bertschinger, A.; Boyd, B. J.; O'Connor, J. M.; Edwards, G. A.; Charman, W. N. Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine J. Pharm. Sci. 2004, 93, 1110-1121
8. Porter, C. J. H.; Kaukonen, A. M.; Boyd, B. J.; Edwards, G. A.; Charman, W. N. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation Pharm. Res. 2004, 21, 1405-1412
9. Shah, N. H.; Carvajal, M. T.; Patel, C. I.; Infeld, M. H.; Malick, A. W. Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs Int. J. Pharm. 1994, 106, 15-23
10. Kommuru, T. R.; Gurley, B.; Khan, M. A.; Reddy, K. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment Int. J. Pharm. 2001, 212, 233-246
11. Kang, B. K.; Lee, J. S.; Chon, S. K.; Jeong, S. Y.; Yuk, S. H.; Khang, G.; Lee, H. B.; Cho, S. H. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs Int. J. Pharm. 2004, 274, 65-73
12. Gao, P.; Guyton, M. E.; Huang, T.; Bauer, J. M.; Stefanski, K. J.; Lu, Q. Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations Drug Dev. Ind. Pharm. 2004, 30, 221-229
13. Araya, H.; Nagao, S.; Tomita, M.; Hayashi, M. The novel formulation design of self-emulsifying drug delivery systems (SEDDS) type O/W microemulsion I: enhancing effects on oral bioavailability of poorly water soluble compounds in rats and beagle dogs Drug Metab. Pharmacokinet. 2005, 20, 244-256
14. Grove, M.; Pedersen, G. P.; Nielsen, J. L.; Müllertz, A. Bioavailability of seocalcitol I: relating solubility in biorelevant media with oral bioavailability in rats-effect of medium and long chain triglycerides J. Pharm. Sci. 2005, 94, 1830-1838
15. Porter, C. J. H.; Pouton, C. W.; Cuine, J. F.; Charman, W. N. Enhancing intestinal drug solubilisation using lipid-based delivery systems Adv. Drug Delivery Rev. 2008, 60, 673-691
16. Constantinides, P. P. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects Pharm. Res. 1995, 12, 1561-1572
17. Pouton, C. W. Formulation of self-emulsifying drug delivery systems Adv. Drug Delivery Rev. 1997, 25, 47-58
18. Pouton, C. W. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and "self-microemulsifying" drug delivery systems Eur. J. Pharm. Sci. 2000, 11, S93-S98
19. Gursoy, R. N.; Benita, S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs Biomed. Pharmcother. 2004, 58, 173-182
20. Gershanik, T.; Benita, S. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs Eur. J. Pharm. Biopharm. 2000, 50, 179-188
21. O'Driscoll, C. M.; Griffin, B. T. Biopharmaceutical challenges associated with drugs with low aqueous solubility: the potential impact of lipid-based formulations Adv. Drug Delivery Rev. 2008, 60, 617-624
22. Tan, E. Y.; Hartmann, G.; Chen, Q.; Pereira, A.; Bradley, S.; Doss, G.; Zhang, A. S.; Ho, J. Z.; Braun, M. P.; Dean, D. C.; Tang, W.; Kumar, S. Pharmacokinetics, metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and Rhesus monkeys Drug Metab. Dispos. 2010, 38, 459-473
23. Perlman, M. E.; Murdande, S. B.; Gumkowski, M. J.; Shah, T. S.; Rodricks, C. M.; Thornton-Manning, J.; Freel, D.; Erhart, L. C. Development of a self-emulsifying formulation that reduces the food effect for torcetrapib Int. J. Pharm. 2008, 351, 15-22
24. Gibson, L. Lipid-Based Excipients for Oral Drug Delivery. In Oral Lipid-Based Formulations: Enhancing the Bioavailability of Poorly Water-Soluble Drugs; Hauss, D., Ed.; Informa Healthcare: New York, London, 2007; pp 33-61.
25. Jannin, V.; Musakhanian, J.; Marchaud, D. Approaches for the development of solid and semi-solid lipid-based formulations Adv. Drug Delivery Rev. 2008, 60, 734-746
26. Pouton, C. W.; Porter, C. J. H. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies Adv. Drug Delivery Rev. 2008, 60, 625-637
27. Devani, M. J.; Ashford, M.; Craig, D. Q. M. The emulsification and solubilisation properties of polyglycolysed oils in self-emulsifying formulations J. Pharm. Pharmacol. 2004, 56, 307-316
28. Rane, S. S.; Anderson, B. D. What determines drug solubility in lipid vehicles: Is it predictable? Adv. Drug Delivery Rev. 2008, 60, 638-656
29. Rane, S. S.; Cao, Y.; Anderson, B. D. Quantitative solubility relationships and the effect of water uptake in triglyceride/monoglyceride microemulsions Pharm. Res. 2008, 25, 1158-1174
30. Cao, Y.; Marra, M.; Anderson, B. D. Predictive relationships for the effects of triglyceride ester concentration and water uptake on solubility and partitioning of small molecules into lipid vehicles J. Pharm. Sci. 2004, 93, 2768-2779
31. Pouton, C. W. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system Eur. J. Pharm. Sci. 2006, 29, 278-287
32. Dahan, A.; Hoffman, A. The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats Eur. J. Pharm. Biopharm. 2007, 67, 96-105
33. Dahan, A.; Hoffman, A. Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: correlation with in vivo data and the relationship to intra-enterocyte processes in rats Pharm. Res. 2006, 23, 2195-2174
34. Cuine, J. F.; Charman, W. N.; Pouton, C. W.; Edwards, G. A.; Porter, C. J. H. Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs Pharm. Res. 2007, 24, 748-757
35. Cuine, J. F.; McEvoy, C. L.; Charman, W. N.; Pouton, C. W.; Edwards, G. A.; Benameur, H.; Porter, C. J. H. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs J. Pharm. Sci. 2008, 97, 995-1012
36. Poelma, F. G. J.; Breas, R.; Tukker, J. J. Intestinal absorption of drugs. III. The influence of taurocholate on the disappearance kinetics of hydrophilic and lipophilic drugs from the small intestine of the rat Pharm. Res. 1990, 7, 392-397
37. Li, P.; Ghosha, A.; Wagnera, R. F.; Krillb, S.; Joshia, Y. M.; Serajuddina, A. T. M. Effect of combined use of nonionic surfactant on formation of oil-in-water microemulsions Int. J. Pharm. 2005, 288, 27-34
38. Nielsen, F. S.; Gibault, E.; Ljusberg-Wahren, H.; Arleth, L.; Pedersen, J. S.; Mullertz, A. Characterization of prototype self-nanoemulsifying formulations of lipophilic compounds J. Pharm. Sci. 2007, 96, 876-892
39. Porter, C. J. H.; Charman, W. N. In vitro assessment of oral lipid based formulations Adv. Drug Delivery Rev. 2001, 50, S127-S147
40. Date, A. A.; Nagarsenker, M. S. Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for cefpodoxime proxetil Int. J. Pharm. 2007, 329, 166-172
41. Kossena, G. A.; Charman, W. N.; Boyd, B. J.; Dunstan, D. E.; Porter, C. J. H. Probing drug solubilization patterns in the gastrointestinal tract after administration of lipid-based delivery systems: a phase diagram approach J. Pharm. Sci. 2004, 93, 332-348
42. Kossena, G. A.; Boyd, B. J.; Porter, C. J.; Charman, W. N. Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water-soluble drugs J. Pharm. Sci. 2003, 92, 634-648
43. Sek, L.; Boyd, B.; Charman, W. N.; Porter, C. J. H. Examination of the impact of a range of Pluronic surfactants on the in-vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone J. Pharm. Pharmacol. 2006, 58, 809-820
44. Patton, J. S.; Carey, M. C. Watching fat digestion Science 1979, 204, 145-148
45. Hernell, O.; Staggers, J. E.; Carey, M. C. Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 2. Phase analysis and aggregation states of luminal lipids during duodenal fat digestion in healthy adult human beings Biochemistry 1990, 29, 2041-2056
46. Staggers, J. E.; Hernell, O.; Stafford, R. J.; Carey, M. C. Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 1. Phase behavior and aggregation states of model lipid systems patterned after aqueous duodenal contents of healthy adult human beings Biochemistry 1990, 29, 2028-2040
47. Devani, M. J.; Ashford, M.; Craig, D. Q. M. The development and characterisation of triglyceride-based "spontaneous" multiple emulsions Int. J. Pharm. 2005, 300, 76-88
48. Kaukonen, A. M.; Boyd, B. J.; Porter, C. J. H.; Charman, W. N. Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations Pharm. Res. 2004, 21, 245-253
49. Sek, L.; Porter, C. J. H.; Kaukonen, A. M.; Charman, W. N. Evaluation of the in-vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products J. Pharm. Pharmacol. 2002, 54, 29-41
50. Hauss, D. Oral lipid-based formulations Adv. Drug Delivery Rev. 2007, 59, 667-676
51. Porter, C. J. H.; Charman, W. N. Oral Lipid-Based Formulations: Using Preclinical Data To Dictate Formulation Strategies for Poorly Water-Soluble Drugs. In Oral Lipid-Based Formulations: Enhancing the Bioavailability of Poorly Water-Soluble Drugs; Hauss, D. J., Ed.; Informa Healthcare: New York, London, 2007; pp 185-205.
52. DeSesso, J. M.; Jacobson, C. F. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats Food Chem. Toxicol. 2001, 39, 209-228
53. Neervannan, S. Preclinical formulations for discovery and toxicology: physicochemical challenges Expert Opin Drug Metab Toxicol. 2006, 2, 715-731
54. Gad, S. C.; Cassidy, C. D.; Aubert, N.; Spainhour, B.; Robbe, H. Nonclinical vehicle use in studies by multiple routes in multiple species Int. J. Toxicol. 2006, 25, 499-521
55. Thomson, A. B.; Schoeller, C.; Keelan, M.; Smith, L.; Clandinin, M. T. Lipid absorption: passing through the unstirred layers, brush-border membrane, and beyond Can. J. Physiol. Pharmacol. 1993, 71, 531-555
56. Shiau, Y. F.; Kelemen, R. J.; Reed, M. A. Acidic mucin layer facilitates micelle dissociation and fatty acid diffusion Am. J. Physiol. 1990, 259 (4, Part 1) G671-G675
57. Constantinides, P. P.; Wasan, K. M. Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies J. Pharm. Sci. 2007, 96, 235-248
58. Cornaire, G.; Woodley, J.; Hermann, P.; Cloarec, A.; Arellano, C.; Houin, G. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo Int. J. Pharm. 2004, 278, 119-131
59. Wang, S. W.; Monagle, J.; McNulty, C.; Putnam, D.; Chen, H. Determination of P-glycoprotein inhibition by excipients and their combinations using an integrated high-throughput process J. Pharm. Sci. 2004, 93, 2755-2767
60. Gao, P.; Rush, B. D.; Pfund, W. P.; Huang, T.; Bauer, J. M.; Morozowich, W.; Kuo, M.-S.; Hageman, M. J. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability J. Pharm. Sci. 2003, 92, 2386-2398
61. Bogman, K.; Zysset, Y.; Degen, L.; Hopfgartner, G.; Gutmann, H.; Alsenz, J.; Drewe, J. P-Glycoprotein and surfactants: effect on intestinal talinolol absorption Clin. Pharm. Ther. 2005, 77, 24-32
62. Nordskog, B. K.; Phan, C. T.; Nutting, D. F.; Tso, P. An examination of the factors affecting intestinal lymphatic transport of dietary lipids Adv. Drug Delivery Rev. 2001, 50, 21-44
63. Hauss, D. J.; Fogal, S. E.; Ficorilli, J. V.; Price, C. A.; Roy, T.; Jayaraj, A. A.; Keirns, J. J. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor J. Pharm. Sci. 1998, 87, 164-169
64. Khoo, S.-M.; Shackleford, D. M.; Porter, C. J. H.; Edwards, G. A.; Charman, W. N. Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs Pharm. Res. 2003, 20, 1460-1465
65. Holm, R.; Porter, C. J. H.; Edwards, G. A.; Müllertz, A.; Kristensen, H. G.; Charman, W. N. Examination of oral absorption and lymphatic transport of halofantrine in a triple-cannulated canine model after administration in self-microemulsifying drug delivery systems (SMEDDS) containing structured triglycerides Eur. J. Pharm. Sci. 2003, 20, 91-97
66. Grove, M.; Nielsen, J. L.; Pedersen, G. P.; Müllertz, A. Bioavailability of seocalcitol IV: evaluation of lymphatic transport in conscious rats Pharm. Res. 2006, 23, 2681-2688
67. Griffin, B. T.; O'Driscoll, C. M. A comparison of intestinal lymphatic transport and systemic bioavailability of saquinavir from three lipid-based formulations in the anaesthetised rat model J. Pharm. Pharmacol. 2006, 58, 917-925
68. Sachs-Barrable, K.; Lee, S. D.; Wasan, E. K.; Thornton, S. J.; Wasan, K. M. Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections Adv. Drug Delivery Rev. 2008, 60, 692-701
69. Porter, C. J. H.; Charman, W. N. Intestinal lymphatic drug transport: an update Adv. Drug Delivery Rev. 2001, 50, 61-80
70. O'Driscoll, C. M. Lipid-based formulations for intestinal lymphatic delivery Eur. J. Pharm. Sci. 2002, 15, 405-415
71. Trevaskis, N. L.; Charman, W. N.; Porter, C. J. H. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update Adv. Drug Delivery Rev. 2008, 60, 702-716
72. Charman, W. N. A.; Stella, V. J. Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules Int. J. Pharm. 1986, 34, 175-178
73. Tso, P.; Buch, K. L.; Balint, J. A.; Rodgers, J. B. Formation and transport of chylomicrons by enterocytes to the lymphatics Am. J. Physiol. 1982, 242, G408-G415
74. Caliph, S. M.; Charman, W. N.; Porter, C. J. H. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats J. Pharm. Sci. 2000, 89, 1073-1084
75. Charman, W. N. A.; Noguchi, T.; Stella, V. J. An experimental system designed to study the in situ intestinal lymphatic transport of lipophilic drugs in anesthetized rats Int. J. Pharm. 1986, 33, 155-164
76. Khoo, S.-M.; Edwards, G. A.; Porter, C. J. H.; Charman, W. N. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine J. Pharm. Sci. 2001, 90, 1599-1607
77. Charman, W. N.; Porter, C. J. H. Lipophilic prodrugs designed for intestinal lymphatic transport Adv. Drug Delivery Rev. 1996, 19, 149-169
78. Shackleford, D. M.; Faassen, W. A.; Houwing, N.; Lass, H.; Edwards, G. A.; Porter, C. J. H.; Charman, W. N. Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs J. Pharmacol. Exp. Ther. 2003, 306, 925-933
79. Yuksel, N.; Karatas, A.; Ozkan, Y.; Savaser, A.; Ozkan, S. A.; Baykara, T. Enhanced bioavailability of piroxicam using Gelucire 44/14 and Labrasol: in vitro and in vivo evaluation Eur. J. Pharm. Biopharm. 2003, 56, 453-459
80. Woo, J. S.; Song, Y. K.; Hong, J. Y.; Lim, S. J.; Kim, C. K. Reduced food-effect and enhanced bioavailability of a self-microemulsifying formulation of itraconazole in healthy volunteers Eur. J. Pharm. Sci. 2008, 33, 159-165
81. Schamp, K.; Schreder, S.-A.; Dressman, J. Development of an in vitro/in vivo correlation for lipid formulations of EMD 50733, a poorly soluble, lipophilic drug substance Eur. J. Pharm. Biopharm. 2006, 62, 227-234
82. Gao, P.; Morozowich, W. Case Studies: Rational Development of Self-Emulsifying Formulations for Improving the Oral Bioavailability of Poorly Soluble, Lipophilic Drugs. In Oral Lipid-Based Formulations: Enhancing the Bioavailability of Poorly Water-Soluble Drugs; Hauss, D., Ed.; Informa Healthcare: New York, London, 2007; pp 273-302.
83. Gao, P.; Morozowich, W. Design and Development of Supersaturatable Self-Emulsifying Drug Delivery Systems for Enhancing the Gastrointestinal Absorption of Poorly Soluble Drugs. In Oral Lipid-Based Formulations: Enhancing the Bioavailability of Poorly Water-Soluble Drugs; Hauss, D., Ed.; Informa Healthcare: New York, London, 2007; pp 303-327.